Tuberculosis Clinical Trial
Official title:
Estimation of Plasma Free and Total Drug Levels of Rifampicin, Isoniazid and Pyrazinamide in Patients on Antituberculosis Therapy and Its Correlation With Development of Drug Induced Hepatotoxicity
The purpose of the study is to estimate plasma drug levels ( free and total drug levels ) of rifampicin and other antituberculosis drugs and compare these drug levels in patients who develop drug induced hepatotoxicity versus those who do not .The study hypothesis is that the ATT drug induced hepatotoxicity is related to free drug levels of rifampicin and other antituberculosis drugs .
Tuberculosis (TB) is a major health problem in both the developing and developed countries
because of its resurgence in the immunosuppressed patients. World Health Organization (WHO)
in 1993 declared tuberculosis to be a 'global emergency' with more than a third of the
world's population infected. Globally 8.9 million new cases of tuberculosis occur annually,
of which 1.8 million (20%) occur in India.
Short-course chemotherapy containing isoniazid (INH), rifampicin (RMP) and pyrazinamide
(PZA) has proved to be highly effective in the treatment of tuberculosis. One of its adverse
effects is hepatotoxicity. It is the most common side effect leading to interruption of
therapy. It is associated with mortality of 6-12% if these drugs are continued even after
the onset of symptoms. Risk of hepatotoxicity is increased when these drugs are combined.
The time interval between the start of anti-TB drugs and appearance of hepatotoxicity varies
from 3 to 135 days. In most cases hepatitis is evident within three months of start of
antituberculosis treatment (ATT).
The pathogenesis of drug-induced hepatotoxicity (DIH) is still not entirely clear for most
anti TB drugs including rifampicin. Hypersensitivity is a definite possibility. Rifampicin
induced hepatitis has been postulated to occur as a part of systemic allergic reaction and
due to unconjugated hyperbilirubinaemia as a result of competition with bilirubin for uptake
at hepatocyte plasma membrane. DIH caused by rifampicin occurs earlier as compared to
isoniazid. While a dose related toxicity may exist, a direct correlation between serum drug
levels and hepatotoxicity has not been well reported. Thus the clinical relevance of
therapeutic monitoring of serum rifampicin concentrations in managing DIH is still being
explored. Rifampicin is highly protein bound and hypoalbuminemia is a known risk factor for
DIH ,so free drug levels in plasma has more significance than total drug levels in plasma.
Present study is done to estimate free and total drug levels of rifampicin and other
antituberculosis drugs in patients on ATT and to compare it between patients who develop DIH
vs those who do not and to assess the predicting ability of these drug levels in the
subsequent development of drug induced hepatoxicity.
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
| Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
| Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
| Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
| Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
| Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
| Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
| Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
| Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
| Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
| Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
| Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
| Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
| Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
| Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
| Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
| Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
| Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |